Table 11.6g

Immunosuppression Use for Maintenance Between Discharge

and One Year Following Transplantation, 1994 to 2003

Recipients with Heart Transplants

  Year of Transplant
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Transplants 2,340 2,363 2,343 2,293 2,348 2,188 2,199 2,202 2,155 2,057
Tx with Follow-up Immunosuppression Info 1,916 1,907 1,932 1,875 1,932 1,768 1,810 1,849 1,815 1,713
Corticosteroids Any in Category 90.2% 90.5% 88.7% 87.6% 89.9% 92.5% 92.2% 90.8% 88.3% 85.5%
Steroids 90.2% 90.5% 88.7% 87.6% 89.9% 92.5% 92.2% 90.8% 88.3% 85.5%
Cyclosporine Any in Category 89.6% 82.2% 84.7% 82.7% 78.5% 81.0% 76.8% 63.9% 56.7% 53.5%
Cyclosporin 81.7% 1.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.0%
Sandimmmune 7.2% 42.6% 19.4% 12.2% 10.4% 7.9% 5.4% 3.4% 2.0% 1.3%
Neoral 0.6% 37.9% 65.3% 70.5% 68.1% 73.0% 67.2% 50.3% 41.9% 38.0%
Gengraf 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 4.1% 9.7% 12.4% 13.5%
Eon 0.1% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.3% 0.3% 0.6%
Tacrolimus Any in Category 3.5% 10.1% 15.1% 17.7% 24.5% 27.1% 30.6% 43.3% 50.1% 53.1%
Tacrolimus 3.5% 10.1% 15.1% 17.7% 24.5% 27.1% 30.6% 43.3% 50.1% 53.1%
Antimetabolites Any in Category 91.0% 89.3% 90.8% 90.4% 90.9% 86.4% 90.8% 89.1% 87.4% 87.9%
Mycophenolate Mofetil 1.9% 11.8% 28.2% 47.3% 56.2% 57.5% 71.9% 74.7% 74.1% 78.2%
Mycophenolate Sodium 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.8% 0.4%
Azathioprine 87.8% 76.2% 61.8% 42.6% 34.2% 28.6% 18.7% 14.4% 12.3% 9.3%
Leflunomide 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0%
Cytoxan 1.3% 1.2% 0.8% 0.5% 0.6% 0.3% 0.2% 0.0% 0.1% 0.0%
mTOR Inhibitors Any in Category 0.1% 0.0% 0.0% 0.2% 0.4% 3.2% 5.0% 7.5% 14.3% 16.6%
Sirolimus 0.1% 0.0% 0.0% 0.2% 0.4% 2.1% 4.7% 7.5% 14.3% 16.6%
Everolimus 0.0% 0.0% 0.0% 0.0% 0.1% 1.0% 0.3% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 2, 2005.

Percentages are calculated based on the total number of patients with any immunosuppression use between discharge and one year following transplantation.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug withinthe same category.